PURPOSE: Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1(R132MUT)) is frequent in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a marker for GBMs that arise by transformation from lower-grade gliomas, regardless of clinical history. To determine how GBMs arising with IDH1(R132MUT) differ from other GBMs, we undertook a comprehensive comparison of patients presenting clinically with primary GBM as a function of IDH1(R132) mutation status. PATIENTS AND METHODS: In all, 618 treatment-naive primary GBMs and 235 lower-grade diffuse gliomas were sequenced for IDH1(R132) and analyzed for demographic, radiographic, anatomic, histologic, genomic, epigenetic, and transcriptional characteristics. RESULTS: Investigation revealed a constellation of features that distinguishes IDH1(R132MUT) GBMs from other GBMs (including frontal location and lesser extent of contrast enhancement and necrosis), relates them to lower-grade IDH1(R132MUT) gliomas, and supports the concept that IDH1(R132MUT) gliomas arise from a neural precursor population that is spatially and temporally restricted in the brain. The observed patterns of DNA sequence, methylation, and copy number alterations support a model of ordered molecular evolution of IDH1(R132MUT) GBM in which the appearance of mutant IDH1 protein is an initial event, followed by production of p53 mutant protein, and finally by copy number alterations of PTEN and EGFR. CONCLUSION: Although histologically similar, GBMs arising with and without IDH1(R132MUT) appear to represent distinct disease entities that arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events. Optimal clinical management should account for the distinction between these GBM disease subtypes.
PURPOSE: Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1(R132MUT)) is frequent in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a marker for GBMs that arise by transformation from lower-grade gliomas, regardless of clinical history. To determine how GBMs arising with IDH1(R132MUT) differ from other GBMs, we undertook a comprehensive comparison of patients presenting clinically with primary GBM as a function of IDH1(R132) mutation status. PATIENTS AND METHODS: In all, 618 treatment-naive primary GBMs and 235 lower-grade diffuse gliomas were sequenced for IDH1(R132) and analyzed for demographic, radiographic, anatomic, histologic, genomic, epigenetic, and transcriptional characteristics. RESULTS: Investigation revealed a constellation of features that distinguishes IDH1(R132MUT) GBMs from other GBMs (including frontal location and lesser extent of contrast enhancement and necrosis), relates them to lower-grade IDH1(R132MUT) gliomas, and supports the concept that IDH1(R132MUT) gliomas arise from a neural precursor population that is spatially and temporally restricted in the brain. The observed patterns of DNA sequence, methylation, and copy number alterations support a model of ordered molecular evolution of IDH1(R132MUT) GBM in which the appearance of mutant IDH1 protein is an initial event, followed by production of p53 mutant protein, and finally by copy number alterations of PTEN and EGFR. CONCLUSION: Although histologically similar, GBMs arising with and without IDH1(R132MUT) appear to represent distinct disease entities that arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events. Optimal clinical management should account for the distinction between these GBM disease subtypes.
Authors: M C Zlatescu; A TehraniYazdi; H Sasaki; J F Megyesi; R A Betensky; D N Louis; J G Cairncross Journal: Cancer Res Date: 2001-09-15 Impact factor: 12.701
Authors: Erica L Jackson; Jose Manuel Garcia-Verdugo; Sara Gil-Perotin; Monica Roy; Alfredo Quinones-Hinojosa; Scott VandenBerg; Arturo Alvarez-Buylla Journal: Neuron Date: 2006-07-20 Impact factor: 17.173
Authors: Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson Journal: Cancer Cell Date: 2010-02-18 Impact factor: 38.585
Authors: Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins Journal: Neuro Oncol Date: 2009-05-12 Impact factor: 12.300
Authors: K Yamashita; A Hiwatashi; O Togao; K Kikuchi; R Hatae; K Yoshimoto; M Mizoguchi; S O Suzuki; T Yoshiura; H Honda Journal: AJNR Am J Neuroradiol Date: 2015-09-24 Impact factor: 3.825
Authors: Shadi Lalezari; Arthur P Chou; Anh Tran; Orestes E Solis; Negar Khanlou; Weidong Chen; Sichen Li; Jose A Carrillo; Reshmi Chowdhury; Julia Selfridge; Desiree E Sanchez; Ryan W Wilson; Mira Zurayk; Jonathan Lalezari; Jerry J Lou; Laurel Ormiston; Karen Ancheta; Robert Hanna; Paul Miller; David Piccioni; Benjamin M Ellingson; Colin Buchanan; Paul S Mischel; Phioanh L Nghiemphu; Richard Green; He-Jing Wang; Whitney B Pope; Linda M Liau; Robert M Elashoff; Timothy F Cloughesy; William H Yong; Albert Lai Journal: Neuro Oncol Date: 2013-01-17 Impact factor: 12.300
Authors: Andrea E Calvert; Alexandra Chalastanis; Yongfei Wu; Lisa A Hurley; Fotini M Kouri; Yingtao Bi; Maureen Kachman; Jasmine L May; Elizabeth Bartom; Youjia Hua; Rama K Mishra; Gary E Schiltz; Oleksii Dubrovskyi; Andrew P Mazar; Marcus E Peter; Hongwu Zheng; C David James; Charles F Burant; Navdeep S Chandel; Ramana V Davuluri; Craig Horbinski; Alexander H Stegh Journal: Cell Rep Date: 2017-05-30 Impact factor: 9.423
Authors: HuyTram N Nguyen; Amy Lie; Tie Li; Reshmi Chowdhury; Fei Liu; Byram Ozer; Bowen Wei; Richard M Green; Benjamin M Ellingson; He-Jing Wang; Robert Elashoff; Linda M Liau; William H Yong; Phioanh L Nghiemphu; Timothy Cloughesy; Albert Lai Journal: Neuro Oncol Date: 2017-03-01 Impact factor: 12.300
Authors: Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski Journal: Acta Neuropathol Date: 2016-09-23 Impact factor: 17.088